Human subjects research comprises a broad spectrum, from testing of new drugs and therapeutics to surveys and questionnaires (in person or online), observation studies, and research with human tissues or data about human beings. It may or may not include direct contact with people.
Anyone performing human subjects research at Harvard, including faculty, staff, and students, must obtain the requisite approvals prior to beginning the project, regardless of funding source.
Harvard has two IRB offices that oversee human research activities:
- Committee on the Use of Human Subjects in Research (CUHS), administered by FAS Research Administration Services (FAS RAS), reviews projects from FAS, GSE, HKS, HBS, HLS, SEAS, GSD, HDS, and the Radcliffe Institute.
- The Office of Human Research Administration, Longwood Medical Area, (OHRA LMA), handles projects that are reviewed by the HMS/HSDM IRB, the Committee on Human Studies, and the HSPH IRB.
Harvard’s IRBs are governed by the Statement of Policies and Procedures Governing the Use of Human Subjects in Research at Harvard University.
The Harvard IRBs share a common Electronic Submission, Tracking and Reporting ESTR which is a web-based system where all researchers submit their applications including completed forms and sample documents.
While the IRBs are the first line of contact for any human-research-related question, human subjects research may require approvals beyond that given by the IRB:
- Research that involves the use of biological, chemical, or radioactive materials in humans may require the approval or signoff from the appropriate area in Lab Safety or may require a Material Transfer Agreement (MTA) to obtain those materials.
- Research performed in collaboration with another institution may require approvals from the collaborating institution.
- Research in foreign countries may require government and/or local research ethics committee approval.
- Research involving genomic data and sharing should comply with the Harvard GDS Policy and Procedures
- Use of stem cells requires the review and approval of the Embryonic Stem Cell Research Oversight (ESCRO) Committee.
- Research must comply with the University’s Research Data Security Policy.
- Some research involving patients and/or medical information may require compliance with HIPAA.
Multi-center research may be eligible for the Common Reciprocal Reliance Agreement, which can allow investigators who are conducting a mutli-center clinical study to request that participating IRBs rely on the review of one center's IRB. Please see the Harvard Catalyst’s cede review website for more information.
Researchers should be aware of the Financial Policy on Human Subjects Payments.